First Tracks director granted options and RSUs

First Tracks Biotherapeutics, Inc. director Magda Marquet received equity-based compensation awards.

Rhea-AI Filing Summary

First Tracks Biotherapeutics, Inc. director Magda Marquet received equity-based compensation awards. She was granted stock options for 7,000 shares of common stock at an exercise price of 17.81 per share, expiring on May 11, 2036, and 2,500 restricted stock units. The options vest in 12 equal monthly installments starting June 12, 2026, while all RSUs vest on the date of the company’s 2027 annual shareholders meeting, in each case subject to continued service.

Insider Trade Summary

Grant/Award: 9,500 shares

Grant/Award 2 txns

Insider Marquet Magda

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	2,500	$0.00	$0.00
Grant/Award	Stock Option (right to buy)	7,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 2,500 contracts (Direct); Stock Option (right to buy) — 7,000 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. F3. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Option grant size: 7,000 shares Option exercise price: 17.81 per share Option expiration: May 11, 2036 +3 more

6 metrics

Option grant size 7,000 shares Stock options to buy common stock granted on May 12, 2026

Option exercise price 17.81 per share Exercise price for 7,000 stock options

Option expiration May 11, 2036 Expiration date of the 7,000 stock options

RSU grant size 2,500 units Restricted stock units linked to common stock

RSU vesting 100% on 2027 meeting date Vests on First Tracks Biotherapeutics’ 2027 annual shareholders meeting

Option vesting schedule 1/12 monthly from June 12, 2026 Monthly vesting until fully vested, subject to service

Key Terms

Restricted Stock Unit, contingent right, vests, stock option, +1 more

5 terms

Restricted Stock Unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration"

vests financial

"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders"

stock option financial

"The stock option vests as to 1/12 of the total shares monthly"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"Stock Option (right to buy) with a conversion or exercise price of 17.8100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Magda Marquet report for First Tracks Biotherapeutics (TRAX)?

Magda Marquet reported receiving equity awards, not market trades. She was granted stock options for 7,000 shares and 2,500 restricted stock units, both tied to First Tracks Biotherapeutics common stock, as part of her compensation for serving as a director.

How many stock options were granted to Magda Marquet at First Tracks Biotherapeutics (TRAX)?

She was granted options covering 7,000 shares of common stock. These options carry an exercise price of 17.81 per share and expire on May 11, 2036, giving her the right to purchase shares if she chooses to exercise before expiration.

What are the terms of the restricted stock units granted to Magda Marquet at TRAX?

Magda Marquet received 2,500 restricted stock units. Each RSU represents a contingent right to receive one common share for no cash consideration, vesting 100% on the date of First Tracks Biotherapeutics’ 2027 annual shareholders meeting, subject to her continued service.

How do Magda Marquet’s stock options at First Tracks Biotherapeutics vest?

The 7,000 stock options vest in 12 equal monthly installments. Vesting begins June 12, 2026, with one-twelfth of the options vesting each month, contingent on Magda Marquet continuing to provide service to First Tracks Biotherapeutics on each vesting date.

Does Magda Marquet’s Form 4/A for TRAX show any stock sales or purchases on the market?

The Form 4/A shows only grant or award acquisitions, not open-market trades. Both reported transactions are coded as awards of derivatives, reflecting compensation in the form of options and restricted stock units rather than buying or selling existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marquet Magda

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	05/12/2026		A		2,500		(2)	(2)	Common Stock	2,500	$0	2,500	D
Stock Option (right to buy)	$17.81	05/12/2026		A		7,000		(3)	05/11/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

This amended Form 4, as originally filed on May 14, 2026, is being filed to correct the amount of stock options and RSUs granted to the Reporting Person. This Form 4 amendment updates both equity awards to reflect 7,000 stock options and 2,500 RSUs originally granted to the Reporting Person on May 12, 2026.

	/s/ Ajim Tamboli, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)